Viemed Healthcare, Inc. (NASDAQ:VMD) Sees Large Drop in Short Interest

Viemed Healthcare, Inc. (NASDAQ:VMD) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 291,200 shares, a drop of 19.4% from the October 31st total of 361,200 shares. Based on an average daily volume of 166,700 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the shares of the company are short sold.

Viemed Healthcare Stock Up 1.3 %

Shares of NASDAQ VMD opened at $8.67 on Monday. The stock has a market capitalization of $337.58 million, a P/E ratio of 32.11 and a beta of 1.43. The stock’s fifty day moving average is $8.61 and its 200 day moving average is $7.62. Viemed Healthcare has a 52 week low of $6.21 and a 52 week high of $10.44. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.19 and a current ratio of 1.31.

Viemed Healthcare (NASDAQ:VMD) last released its earnings results on Wednesday, November 6th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The firm had revenue of $58.00 million for the quarter. Viemed Healthcare had a net margin of 4.87% and a return on equity of 8.72%.

Insider Transactions at Viemed Healthcare

In related news, Director Randy E. Dobbs sold 36,261 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $9.28, for a total transaction of $336,502.08. Following the sale, the director now owns 107,706 shares of the company’s stock, valued at $999,511.68. This represents a 25.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nitin Kaushal sold 5,995 shares of Viemed Healthcare stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $8.58, for a total value of $51,437.10. Following the completion of the transaction, the director now directly owns 126,843 shares of the company’s stock, valued at $1,088,312.94. This represents a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,256 shares of company stock worth $674,739. Company insiders own 20.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in shares of Viemed Healthcare by 342.3% in the 3rd quarter. Barclays PLC now owns 53,439 shares of the company’s stock valued at $392,000 after purchasing an additional 41,358 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Viemed Healthcare by 91.2% during the 3rd quarter. National Bank of Canada FI now owns 3,346 shares of the company’s stock worth $25,000 after buying an additional 1,596 shares during the last quarter. Wasatch Advisors LP lifted its position in shares of Viemed Healthcare by 19.6% during the 3rd quarter. Wasatch Advisors LP now owns 1,848,884 shares of the company’s stock worth $13,552,000 after buying an additional 303,277 shares during the last quarter. Raffles Associates LP boosted its stake in Viemed Healthcare by 11.0% in the third quarter. Raffles Associates LP now owns 402,691 shares of the company’s stock valued at $2,952,000 after buying an additional 40,000 shares in the last quarter. Finally, PDT Partners LLC bought a new position in Viemed Healthcare in the third quarter valued at about $78,000. 74.24% of the stock is currently owned by institutional investors and hedge funds.

About Viemed Healthcare

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.